A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease
MP Sovani, CI Whale, AE Tattersfield - Drug Safety, 2004 - Springer
The two inhaled long-acting β 2-adrenoceptor agonists, salmeterol and formoterol, have
been studied extensively since their introduction in the early 1990s. In this review we …
been studied extensively since their introduction in the early 1990s. In this review we …
A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease
MP Sovani, CI Whale, AE Tattersfield - Drug safety, 2004 - pubmed.ncbi.nlm.nih.gov
The two inhaled long-acting beta2-adrenoceptor agonists, salmeterol and formoterol, have
been studied extensively since their introduction in the early 1990s. In this review we …
been studied extensively since their introduction in the early 1990s. In this review we …
A benefit-risk assessment of inhaled long-acting [[beta]. sub. 2]-agonists in the management of obstructive pulmonary disease
MP Sovani, CI Whale, AE Tattersfield - Drug Safety, 2004 - go.gale.com
The two inhaled long-acting [[beta]. sub. 2]-adrenoceptor agonists, salmeterol and
formoterol, have been studied extensively since their introduction in the early 1990s. In this …
formoterol, have been studied extensively since their introduction in the early 1990s. In this …
A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease.
MP Sovani, CI Whale, AE Tattersfield - Drug Safety, 2004 - europepmc.org
The two inhaled long-acting beta2-adrenoceptor agonists, salmeterol and formoterol, have
been studied extensively since their introduction in the early 1990s. In this review we …
been studied extensively since their introduction in the early 1990s. In this review we …
[引用][C] A benefit-risk assessment of inhaled long-acting β2-agonists in the management of obstructive pulmonary disease
MP SOVANI, CI WHALE, AE TATTERSFIELD - Drug safety, 2004 - pascal-francis.inist.fr
A benefit-risk assessment of inhaled long-acting β2-agonists in the management of
obstructive pulmonary disease CNRS Inist Pascal-Francis CNRS Pascal and Francis …
obstructive pulmonary disease CNRS Inist Pascal-Francis CNRS Pascal and Francis …
[引用][C] A Benefit-Risk Assessment of Inhaled Long-Acting?? 2-Agonists in the Management of Obstructive Pulmonary Disease
MP Sovani, CI Whale, AE Tattersfield - Drug Safety, 2004 - cir.nii.ac.jp
A Benefit-Risk Assessment of Inhaled Long-Acting ??2-Agonists in the Management of
Obstructive Pulmonary Disease | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
Obstructive Pulmonary Disease | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease.
MP Sovani, CI Whale, A Tattersfield - Drug Safety, 2004 - search.ebscohost.com
The two inhaled long-acting β2-adrenoceptor agonists, salmeterol and formoterol, have
been studied extensively since their introduction in the early 1990s. In this review we …
been studied extensively since their introduction in the early 1990s. In this review we …